Evidence map›Paper›PMID 28685479›Full record

Review3 Biotech2017

Neoteric trends in tissue culture-mediated biotechnology of Indian ipecac [Tylophora indica (Burm. f.) Merrill].

Saikat Gantait, Suprabuddha Kundu

Abstract readReview
In one paragraph

Review in 3 Biotech, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Journal, genetic engineering & biotechnology · 2018
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Saikat GantaitAICRP on Groundnut, Directorate of Research, Bidhan Chandra Krishi Viswavidyalaya, Kalyani, Nadia, West Bengal, 741235, India. saikatgantait@yahoo.com.ORCID http://orcid.org/0000-0001-5059-2428
Suprabuddha KunduDepartment of Agricultural Biotechnology, Faculty of Agriculture, Bidhan Chandra Krishi Viswavidyalaya, Mohanpur, Nadia, West Bengal, 741252, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tylophora indica (Burm. f.) Merrill, an ethno-pharmacologically important perennial climber of Asclepiadaceae, is commonly known as Antamul or Indian ipecac. It is essentially accredited for its medicinal properties owing to its wide range of alkaloids in the form of bioactive secondary metabolites, such as tylophorine, tylophorinine, and tylophorinidine. Accelerated mass propagation of Tylophora is challenging because of its reduced seed germination frequency that consequently headed the pursuit for efficient protocols on in vitro propagation for the large-scale regeneration, conservation as well as sustainable supply of quality propagules. Ample tissue culture-mediated biotechnological investigations have been carried out on this medicinal plant till date and several micropropagation protocols have been standardized as well. The present review compares between several typical methods as well as factors, involving on direct and indirect organogenesis of Tylophora along with various up-to-date and modified techniques such as somatic embryogenesis, protoplast culture, synthetic seed production, genetic transformation, and in vitro interventions for the secondary metabolite production that have been reported in last two decades. This compilation will allow assessing the achievements and trends of Tylophora research so far, as well as will advance the research more rapidly, since many aspects, basic and applied, have yet to be explored.

Indexed as

Genetic transformationIn vitroMedicinal plantOrganogenesisSomatic embryogenesisSynthetic seedsTylophorine

Identifiers

PMID28685479
PMCPMC5500466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.